Glucagon-like peptide-1 (GLP-1) receptor agonists have reshaped the therapeutic landscape of type 2 diabetes and obesity in a way few drug classes have achieved in recent decades. What began as a glucose-lowering strategy has rapidly evolved into a cornerstone of cardiometabolic risk management, with implications that extend well beyond glycemic control.
Large cardiovascular outcomes trials have been pivotal in this transition. Weekly subcutaneous semaglutide has demonstrated a reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease, even in the absence of diabetes. Subsequent kidney outcome analyses from the SELECT program further suggest cardiorenal benefits independent of glycemic effects [1].
Collectively, these data have repositioned GLP-1 therapies from metabolic adjuncts to foundational cardiometabolic interventions. The market has responded accordingly.
Between 2019 and 2023 in the United States, prescriptions for GLP-1 receptor agonists among non-diabetic patients increased by approximately 700% [2].
During the same period, national spending for GLP-1 therapies rose from $18.5 billion to $71.7 billion, reflecting a near 400% increase. These figures reflect not only broader clinical indications, but also the transition of GLP-1 therapies into high-volume, long-duration treatments intended for chronic disease management.
Although the discussion below primarily references GLP‑1 receptor agonists, the strategic considerations are broadly applicable to the expanding class of incretin-based therapies, including emerging dual and multi-receptor agonists.
The persistence paradox
Yet, beneath this growth lies a critical challenge: persistence. Real-world data tell a more complicated story than clinical trials. In a large U.S. cohort study published in JAMA Network Open in 2025, discontinuation rates of GLP-1 therapy were substantial.
Among patients with type 2 diabetes, 46.5% discontinued therapy within one year, rising to 64.1% at two years [3]. Discontinuation was even more pronounced among individuals without diabetes, reaching 64.8% at one year and 84.4% at two years [3].
Despite evidence that stopping GLP-1 therapy can lead to rapid weight regain and worsening cardiometabolic parameters, reinitiation rates were modest — 47.3% among patients with type 2 diabetes and 36.3% among those without [3]. Injectable therapies like GLP-1 tend to have lower persistence and higher discontinuation than oral agents like metformin or sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes [4].
Discontinuation could be due to many reasons such as gastrointestinal side effects, high costs, inconvenience of injection schedules, or even inadequate blood glucose control for patients with diabetes [4].
These findings underscore an essential point: the durable benefits of injectable GLP-1 therapy are contingent on sustained exposure. Short-term use of therapies for chronic disease management of diabetes does not deliver the full cardiometabolic value demonstrated in trials. Persistence is now the primary value determinant in GLP-1 markets, and technological architecture is a controllable lever to improve it.
Expanding the definition of precision and personalization
The divergence between strong efficacy in controlled trials and high discontinuation in routine practice raises a fundamental question: if the molecule performs reliably, what limits its adherence in the real world? Gastrointestinal adverse effects, cost, and access constraints are important contributors, but they do not fully explain the behavioral and experiential realities of chronic injectable therapy.
GLP-1 receptor agonists that are administered subcutaneously typically require structured dose escalation and long-term adherence over years, often across increasingly heterogeneous populations that include older adults and individuals with multiple comorbidities who may face physical, cognitive, or logistical barriers to consistent self-injection.
Historically, precision in metabolic disease has centered on molecular targeting, biomarker stratification, and individualized dose selection, positioning precision primarily at the pharmacologic level.
In long-term injectable therapy, however, precision extends beyond the molecule to encompass how treatment is delivered and experienced. Precision ensures technical reliability, meaning accurate dose delivery with consistent force and timing under varied conditions, and remains foundational for regulatory approval and patient safety. Yet translating pharmacologic precision into durable real-world outcomes requires personalization at the level of delivery, aligning technology design with the practical demands of chronic use.
Personalization, by contrast, concerns adaptability to patient variability.
It reflects how well the delivery system accommodates differences in anatomy, dexterity, tolerance, behavioral patterns, and treatment context. Personalization may include flexible dose architectures that align with real-world titration patterns, injection dynamics that improve comfort and confidence, and digital integration that supports adherence and feedback. Whereas precision ensures the technology works as intended, personalization ensures it works for the patient.
A highly efficacious molecule cannot compensate for suboptimal injection technique, anxiety around self-administration, titration complexity, or ergonomic limitations.
Even in chronic conditions such as type 2 diabetes, where patients may have prior experience with injectable therapies including insulin or GLP 1 agents, the cumulative burden of repeated self-injection over years can influence confidence, comfort, and adherence.
Factors such as injection force, needle geometry, device grip design, dose escalation architecture, and digital adherence integration may meaningfully influence persistence. While these delivery-related dimensions directly affect real-world outcomes, they have historically received less strategic emphasis than receptor pharmacodynamics and molecular optimization.
As GLP1 therapies progress to deliver their full cardiometabolic promise, various routes of administration need to be considered. The key to therapeutic optimization is to determine the most appropriate method of administration for each patient, which provides an avenue for delivery system innovation. Technological customization that accounts for patient anatomy, dexterity, behavioral patterns, and treatment context could represent a critical lever for improving long-term adherence. However, personalization can also be evaluated through the lens of sustainability, both environmental and operational.
As chronic injectable therapies expand to millions of patients over multiyear horizons, the cumulative material and operational footprint of single-use, fixed-dose autoinjectors becomes increasingly significant.
A personalized medicine paradigm that relies exclusively on disposable architectures may prove difficult to sustain economically and environmentally at scale. Multidose and adjustable dose platforms offer a more durable alternative by consolidating dose flexibility within a single device, reducing discarded components during titration, streamlining distribution, and improving supply chain efficiency. In high-volume GLP-1 markets, these efficiencies are amplified.
Sustainability in this context extends beyond environmental impact to encompass lifecycle management and platform strategy.
Modular multidose architectures can accommodate new dose strengths or combination therapies without requiring full device redesign, thereby minimizing redundant tooling, limiting regulatory resubmissions, and preserving manufacturing continuity. However, these systems introduce additional engineering and regulatory requirements, including sterility assurance across repeated use, maintenance of dose accuracy over multiple actuations, and appropriate patient training. True sustainability therefore depends on balancing material reduction and platform reuse with durability, usability, and uncompromised safety.
As the GLP‑1 class matures, the next phase of innovation may be defined not only by aligning biological efficacy with delivery system personalization, but by ensuring that such personalization can scale responsibly. In an era where long-term outcomes hinge on sustained therapy, the lived experience of injection and the sustainability of the delivery model may prove just as important as receptor binding affinity.
For pharmaceutical developers, device engineers, payors, providers, and healthcare systems alike, the strategic imperative is clear: maximizing the value of GLP-1 therapies requires looking beyond the molecule to the totality of the therapeutic experience.
Three domains of technological personalization
As incretins and GLP‑1 therapies mature into long-term standards of care across expanding populations, competitive differentiation is shifting beyond molecular innovation.
Clinical efficacy among leading agents is converging, indications are broadening to include conditions such as metabolic dysfunction-associated steatohepatitis, obstructive sleep apnea, and chronic kidney disease, and payer scrutiny of persistence and health economic value is intensifying. Increasingly, stakeholders demand real-world evidence that sustained therapy delivers durable clinical benefit and measurable reductions in total cost of care.
In this environment, the delivery system is no longer a passive administration tool but an integrated component of the therapeutic value proposition. Technological personalization refers to the intentional design of delivery platforms that accommodate differences in patient physiology, dexterity, treatment stage, and behavioral patterns while maintaining scalability and commercial viability.
It encompasses adjustable dose architectures that support individualized titration and maintenance, injection dynamics engineered for comfort and confidence across diverse users, and digital integration that reinforces adherence and enables data-driven support.
For pharmaceutical companies, adopting technological personalization requires platform thinking rather than bespoke customization. The objective is not to create fragmented, niche technology, but to develop modular, reusable architectures that can be configured for different patient segments without materially increasing manufacturing complexity or eroding margins. This may involve separating core injection engines from interchangeable functional modules, standardizing components across indications, and leveraging shared validation pathways to minimize incremental regulatory burden. Strategic investment in scalable design, supply chain efficiency, and lifecycle extensibility becomes essential to balance personalization with cost discipline.
As GLP 1 therapies continue to expand across heterogeneous populations and long-term use cases, three domains are emerging as strategically significant: dose architecture flexibility, injection dynamics optimization, and digital integration within a connected ecosystem.
Domain 1: Dose architecture flexibility
Dose architecture flexibility addresses how therapy evolves and how the device can accommodate that evolution without compromising safety or simplicity. GLP-1 regimens commonly require structured escalation to manage gastrointestinal tolerability, yet real-world titration frequently diverges from clinical trial schedules, often characterized as delayed escalation, dose stagnation, or early discontinuation.
In a nationwide Danish cohort of more than 110,000 semaglutide users, only 10% followed the recommended 4-week dose-escalation schedule, and just 13% reached the 2.4 mg maintenance dose by their fifth prescription [5]. This illustrates a measurable gap between protocol-driven dose progression in randomized trials and the delayed, incomplete, or interrupted titration patterns observed in routine care, reinforcing the strategic value of flexible dose architectures that can accommodate real-world variability.
Adjustable dose or multi-dose systems better align with long-term clinical workflows by supporting individualized maintenance regimens and smoother titration pathways. From a lifecycle perspective, flexible platforms can enable adaptation for future combination incretin therapies or additional indications.
Architecturally, this requires clear separation between the core injection engine and the dose-setting subsystem, allowing modular adaptation while preserving validated mechanical performance. Commercial autoinjector platforms such as Ypsomed’s YpsoMate [6] and SHL Medical’s Molly[7] exemplify this modular architecture, allowing feature customization and lifecycle evolution without redesign of the foundational delivery mechanism. In practice, this approach can reduce development timelines, localize design changes within defined subsystems, and limit the regulatory burden associated with revalidating fully integrated device architectures.
However, variable dose systems increase regulatory complexity. Under FDA’s combination-product rules, enabling multiple dosage strengths in one device can effectively create a new product for each setting. For example, FDA defines a combination product to include any drug-device pairing where the labeling would require revision to reflect a "significant change in dose" [8]. In practice, this means each selectable dose in an adjustable autoinjector must be verified and validated separately, with clear labeling and human-factor controls to prevent misuse. A precedent exists in the GLP‑1 category itself.
Saxenda (liraglutide) is supplied as a prefilled, multidose pen that enables patients to dial discrete dose increments of 0.6 mg up to a 3.0 mg maintenance dose [9]. The FDA-approved labeling specifies the structured weekly titration schedule and prohibits use outside defined increments, reflecting the need for validated dose accuracy and controlled human-factor design across the full selectable range. Each dialed dose is required to meet performance specifications, and the dosing architecture is explicitly integrated into regulatory review and labeling requirements.
Manufacturers demonstrate dose accuracy and safe operation across the entire adjustment range under worst-case environmental and tolerance conditions as part of technology development activities. Human factors validation addresses the risk of mis-selection, incomplete activation, and user misunderstanding.
Design control documentation, verification testing across all dose settings, and clear labeling strategies become central to regulatory acceptance, consistent with FDA design control requirements that mandate verification that design outputs meet input requirements and validation under actual or simulated use conditions [10].
Domain 2: Injection dynamics
Injection dynamics optimization represents a second dimension of differentiation with the potential to influence patient experience and support long-term adherence. As GLP-1 formulations become more concentrated and/or injection volumes increase, force profile, flow rate, and duration become more perceptible.
The interaction between spring mechanics, formulation viscosity, needle gauge, and ergonomic design shapes perceived comfort and confidence.
In a large survey of 1092 patients on injectable diabetes medications, “injection concerns (42%) such as aversion to needles, pain, or needle size” were the most commonly reported barrier to continuing therapy, which suggests that even incremental improvements in injection experience can influence adherence over multiyear therapy horizons [11].
Mechanical platforms rely on precise spring calibration and friction management to maintain consistent delivery performance across temperature and viscosity ranges. Electromechanical systems introduce the possibility of controlled flow profiles and adaptive force modulation, but they also add complexity in terms of power management and system validation. From a regulatory standpoint, User Interface design for injection supports device performance.
Hence: "FDA notes that these injectors are intended to provide an accurate method of injecting a dose and that they may 'improve dosing accuracy and increase patient compliance’, linking injection engineering directly to safety and effectiveness” [12]. Verification testing characterizes force and flow consistency under stressed conditions, and human factors studies confirm that modifications intended to enhance comfort do not introduce new use errors. Engineering refinement therefore balances experiential improvement with operational simplicity and reliability.
Domain 3: Digital integration
Digital integration introduces a third layer of personalization that extends beyond mechanical performance into behavioral and data-driven domains. Smart autoinjectors embedded with microelectronics and connectivity can automatically log injection events and transmit data to companion apps or cloud platforms. Within a connected ecosystem, these devices may integrate with digital therapeutics, provider dashboards, and manufacturer support programs.
Such systems enable objective adherence tracking and real-time feedback loops, reducing reliance on patient recall. As health care costs associated with nonadherence have grown to $100-300 billion annually, the capability to improve adherence is especially valuable for providers and care teams [13]. Evidence shows that high medication adherence is linked to significantly better clinical outcomes and lower mortality, whereas non-adherence is associated with more hospital admissions and higher healthcare costs. By identifying lapses in use early and enabling timely intervention, digital-enabled injections help sustain patient engagement and the full benefits of therapy.
Advanced analytics can identify early signs of declining adherence, delayed titration, or patterns that precede discontinuation, enabling targeted intervention strategies. Such methods could include proactive outreach via notification systems, home delivery enrollment for refills, titration and injection technique coaching, or personalized education content. In high-cost chronic therapies, these capabilities support real-world evidence generation and value-based care discussions. Architecturally, digital-enabled devices require layered system design encompassing mechanical subsystems, embedded electronics, firmware, secure communication protocols, and cloud infrastructure. Reliability expectations remain equivalent to purely mechanical systems despite the added complexity. Regulatory oversight expands to include software lifecycle validation, cybersecurity risk management, and data privacy compliance. Depending on functionality, elements of the system may be evaluated under the FDA’s Software as a Medical Device (SaMD) regulatory framework [14]. Ongoing firmware maintenance, vulnerability management, and post-market surveillance planning become integral to the product lifecycle.
Individually, each domain provides incremental differentiation. Collectively, they reposition the autoinjector as an adaptive therapeutic platform rather than a static delivery component. Dose flexibility aims to support clinical personalization, injection optimization seeks to improve experiential quality, and digital connectivity offers the potential to enable behavioral personalization. For executive leadership, the strategic decision is not whether personalization is possible, but which combination of architectural investments aligns with long-term franchise strategy, regulatory tolerance, organizational capability, and expected return on persistence-driven value.
Regulatory and practical realities
Innovation in GLP‑1 delivery systems operates within a complex regulatory framework for combination products. Adjustable-dose mechanisms, programmable features, and connected components may expand the scope of required human factors studies, software validation documentation, and cybersecurity risk assessments. Global regulatory alignment further complicates development strategies, particularly when devices are intended for use across multiple markets with differing requirements. Early coordination among device engineering, regulatory affairs, quality, and pharmacovigilance teams is essential to ensure that personalization strategies remain feasible and compliant. Importantly, not every GLP‑1 therapy will warrant advanced device customization. Innovation is most effective when proportionate to clinical need and clearly aligned with patient benefits.
The growing convergence between injectable therapies and wearable health technologies further expands regulatory considerations. In metabolic care, adoption of continuous glucose monitoring has accelerated rapidly; in 2024, the FDA cleared the first over-the-counter CGM for adults not using insulin, broadening wearable access beyond traditional diabetes populations [15]. As GLP‑1 therapies increasingly intersect with wearable-driven data ecosystems, integration of injectors with consumer sensors, mobile applications, and cloud-based analytics introduces additional requirements for software validation, cybersecurity risk management, interoperability controls, and data privacy compliance.
Scaling Customization in High-Volume Markets
The scale of GLP‑1 manufacturing presents both opportunities and constraints. These therapies are produced and distributed at volumes rarely seen in injectable biologics, and any device innovation therefore requires compatibility with high-throughput, globally distributed supply chains. Customization cannot come at the expense of manufacturing robustness. Platform-based architectures provide one potential pathway forward, enabling standardized core components to be combined with configurable features that support differentiated offerings.
Modular approaches, including software algorithm updates and firmware enhancements, can enable incremental platform evolution.
For example, Dexcom’s CGM systems have progressed through iterative sensor refinements and mobile app feature updates while expanding manufacturing automation and scale [16]. With the 2024
FDA clearance of its over‑the‑counter Stelo CGM
, personalization was further extended through software-enabled data insights, reflecting continued evolution of the platform without fundamental redesign of the core sensing architecture [17]. This allowed individualized metabolic feedback and behavioral optimization without disrupting validated production processes, demonstrating how modular, platform-based architectures can scale while supporting personalized care.
Throughout this evolution, sterility assurance, mechanical reliability, and quality system integrity remain non-negotiable. In chronic therapy markets, even small failure rates can have significant consequences, affecting patient safety and treatment continuity while also creating substantial commercial and reputational risk.
Risk of over-engineering
While device personalization offers compelling opportunities, over-engineering poses significant risks. Additional features can increase cost structures, extend development timelines, and introduce regulatory complexity. Excessively sophisticated interfaces may overwhelm users who prioritize simplicity and predictability in managing chronic disease. The most effective precision delivery solutions may be those that quietly reduce friction and cognitive burden rather than those that showcase technological sophistication. A disciplined innovation strategy, grounded in human factors research, real-world usage data, and clearly defined clinical objectives, is essential to ensure that added functionality translates into meaningful patient benefit.
Conclusion
The first phase of incretin/GLP‑1 innovation was defined by molecular breakthroughs for duration of effect and expanding indications. As the therapeutic category matures, differentiation may increasingly depend on how therapy is experienced and sustained. Adherence, comfort, workflow integration, and data-enabled support are emerging as strategic variables in chronic injectable care. Personalized medicine in the GLP‑1 era may therefore extend beyond receptor pharmacology to encompass delivery system design informed by patient preference. By aligning dose flexibility, injection dynamics, and digital integration with the realities of long-term therapy, manufacturers can influence not only how treatment is initiated, but how it is maintained. The next phase of GLP‑1 category leadership may be shaped not solely by what the molecule achieves in trials, but by alternate routes of administration and what the delivery system sustains in practice.
References
[1] A. Michael Lincoff, Kirstine Brown‐Frandsen, Colhoun, H. M., Deanfield, J., Emerson, S. S., Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Kahn, S. E., Kushner, R. F., Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine, 389(24).
https://doi.org/10.1056/nejmoa2307563
[2] Chao, A. M., Gilden, A., & Wadden, T. A. (2026). Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety. PLoS Medicine, 23(1), e1004871–e1004871.
https://doi.org/10.1371/journal.pmed.1004871
[3] Rodriguez, P. J., Zhang, V., Gratzl, S., Do, D., Cartwright, B. G., Baker, C., Gluckman, T. J., Stucky, N., & Emanuel, E. J. (2025). Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity. JAMA Network Open, 8(1), e2457349–e2457349. https://doi.org/10.1001/jamanetworkopen.2024.57349
[4] Lee, D. S. U., & Lee, H. (2022). Adherence and persistence rates of major antidiabetic medications: a review. Diabetology & metabolic syndrome, 14(1), 12. https://doi.org/10.1186/s13098-022-00785-1
[5] Ladebo, L., Ernst, M. T., Aurélie Mailhac, Dirksen, C., Bojsen-Møller, K. N., & Pottegård, A. (2024). Real-World Use of Semaglutide for Weight Management: Patient Characteristics and Dose Titration—A Danish Cohort Study. Diabetes Care, 47(10), 1834–1837.
https://doi.org/10.2337/dc24-1082
[6] YpsoMate | 1 mL Two-Step Prefilled Autoinjector for GLP-1 & Others - Ypsomed. (2025). Ypsomed.com.
https://www.ypsomed.com/en/products/autoinjectors/ypsomate
[7] Addressing the “customizable platform” paradox with a modular device design approach. (2020). Shl-Medical.com; SHL Medical.
https://www.shl-medical.com/news-insights/publications/addressing-the-customizable-platform-paradox-with-a-modular-device-design-approach
[8] 21 CFR 3.2 | Definitions. | eCFR.io. (2026). ECFR.io.
https://ecfr.io/Title-21/Section-3.2
#
[9] U.S. Food and Drug Administration. (2023). Saxenda (liraglutide) injection prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf
[10] US Food and Drug Administration. 21 CFR §820.30—Design controls. Code of Federal Regulations. Revised April 1, 2024.
[11] Spain, C. V., Wright, J. J., Hahn, R. M., Wivel, A., & Martin, A. A. (2016). Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes. Clinical Therapeutics, 38(7), 1653-1664.e1.
https://doi.org/10.1016/j.clinthera.2016.05.009
[12] Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products. (2017). Docslib.
https://docslib.org/doc/713308/technical-considerations-for-pen-jet-and-related-injectors-intended-for-use-with-drugs-and-biological-products
#
[13] McGuire, M., & Iuga, A. (2014). Adherence and Health Care Costs. Risk Management and Healthcare Policy, 7, 35–44.
https://doi.org/10.2147/rmhp.s19801
[14] International Medical Device Regulators Forum. (2013, December 9). Software as a Medical Device (SaMD): Key Definitions. https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-131209-samd-key-definitions-140901.pdf
[15] Commissioner, O. of the. (2024, March 6). FDA Clears First Over-the-Counter Continuous Glucose Monitor. FDA.
https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose-monitor
[16] DexCom, Inc. (2023). 2022 annual report. https://s201.q4cdn.com/758408164/files/doc_financials/2022/ar/d439095dars.pdf
[17] Klein, J. (2024, October 30). Dexcom Stelo: the 200 Best Inventions of 2024. TIME; Time.
https://time.com/collections/best-inventions-2024/7094684/dexcom-stelo/